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Serum metalloproteinases MMP-2, MMP-9, and
metalloproteinase tissue inhibitors in patients are
associated with arteriovenous fistula maturation
Eugene S. Lee, MD, PhD, Qiang Shen, MD, PhD, Robert L. Pitts, BS, Mingzhang Guo, DVM, PhD,
Mack H. Wu, MD, Sue C. Sun, MD, and Sarah Y. Yuan, MD, PhD, Sacramento, Calif
Objective: Many vascular surgeons construct arteriovenous fistulas (AVFs) for hemodialysis access as the primary choice
access. A significant number of AVFs fail to mature, however, leading to patient frustration and repeated operations.
Metalloproteinase (MMP) activity, particularly MMP-2 and MMP-9, may be important for AVF maturation. We
therefore sought to identify whether serum MMP levels could serve as a biomarker for predicting future successful AVF
maturation.
Methods: Blood was collected from patients with chronic renal insufficiency at the time of surgery for long-term
hemodialysis access. Serum was separated from whole blood and ultracentrifuged at 1000g for 10 minutes. Serum
aliquots were frozen at –80°C until used for analysis. Enzyme-linked immunosorbent assay was used to assay levels of
MMP-2, MMP-9, and tissue inhibitor of metalloproteinase type 2 (TIMP-2), and TIMP type 4 (TIMP-4). Clinical end
points were used to divide patients into failed andmatured AVF groups. Successful maturation was considered in patients
who had specific duplex findings or 1month of successful two-needle cannulation hemodialysis. MMP/TIMP ratios were
calculated as an index of the MMP axis activity because MMP activity parallels alterations in TIMP levels.
Results: Of 20 enrolled patients, AVF maturation was successful in 13 and failed in 7. Serum levels of MMP-2/TIMP-2
were significantly higher in patients with matured AVFs vs levels in those that failed (P .003). Similarly, a trend toward
increased serum levels of MMP-9/TIMP-4 was found in patients with successful AVF (P  .06).
Conclusions:MMP-2 and TIMP-2 levels were different among patients whose AVFmatured vs those who did not. Further
follow-up studies to determine the predictability of AVF maturation using relative patient serum levels of MMP-2 and
TIMP-2 should be performed. (J Vasc Surg 2011;54:454-60.)
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tMost patients with end-stage renal failure require he-
modialysis, and the arteriovenous fistula (AVF) is the pre-
ferred method for access. AVFs are the most durable, are
resistant to infection and thrombosis, and are preferred for
lower mortality and cost profiles.1 Recognizing the superi-
ority of this access, the National Kidney Foundation rec-
ommends an aggressive approach to the creation of AVFs.2
However, 20% to 60% of primary AVFs fail to develop into
a functioning dialysis access.3,4 Impaired vein remodeling,
intimal hyperplasia, technical problems, unrecognized ste-
noses within the outflow vein, inflow problems, or steal
syndromes can all lead to failure of achieving a mature AVF.
Vascular access failure is the most important cause for
morbidity, repeat surgery, and hospitalization.5 Given the
challenges of successful access surgery, the biochemical and
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454athologic changes associated with AVF maturation and
ntimal hyperplasia should be sought. Recent studies have
hown that matrix metalloproteinases (MMP) are impor-
ant in the process of AVF maturation.6,7 MMPs belong to
group of zinc-dependent proteases capable of degrading
xtracellular matrix (ECM) proteins.8,9 In particular,
MP-2 is expressed by a variety of cell types and is acti-
ated by membrane-bound membrane type-1 (MT1-
MP) and is inhibited by tissue inhibitor metalloproteinases
ype 2 (TIMP-2).10MMP-9 is also expressed by a variety of
ell types and is inhibited by TIMP type 4 (TIMP-4).
ecause increased expression of MMP-2 and MMP-9 has
een found in the outflow vein tissue, after AVF construc-
ion,7,11 MMP expression in patient serum at the time of
he initial surgery may serve as an important biomarker of
VF maturation. In this study, we sought to identify
hether patient serum MMP expression and inhibition are
ssociated with successful AVF maturation.
ETHODS
Human study methods. A prospective evaluation of
atients undergoing AVF construction for chronic renal
nsufficiency was performed under Institutional Review
oard approval at the Northern California Veterans Affairs
ealth Care System. All patients were enrolled and moni-
ored at the Sacramento Veterans Affairs Medical Center,
nd provided written consent.
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Volume 54, Number 2 Lee et al 455A patient history and physical examination was per-
formed and pertinent medical history documented. Preop-
erative vein mapping without a tourniquet was done using
duplex ultrasound imaging to document vein diameter,
patency, and arterial patency of both upper extremities. As
specified in the 2006 Dialysis on Quality Initiative (DOQI)
vascular access guidelines,12 a radial artery diameter of
0.2 cm and a vein diameter of 0.2 cm at the wrist or
0.3 cm at the antecubital fossa was a requirement for
primary AVF. The minimum diameter was also a determi-
nant in the location in which the AVF would be con-
structed. Both arms were mapped in all patients, and the
most distal vein segment in the nondominant arm was used
if all diameter criteria were met.
Local anesthesia, with monitored anesthesia care, was
used for the construction of the AVF. The arterial and
venous segments were dissected according to routine sur-
gical care. At the time of surgery, 20 mL of blood was
obtained from the open artery via an 18-gauge angiocath-
eter. Blood samples were immediately placed in heparin-
containing tubes (green-top tubes) and kept at room tem-
perature for immediate transport to the laboratory.
Immediate centrifugation and preparation was per-
formed2 hours of sample collection. Once a serum pellet
was collected, the sample was kept at –80°C for later
Table. Data for all patients within the studya
Pt Age  SD Procedure DM
1 52 Wrist Y
2 48 Wrist N
3 54 BB N
4 67 BB Y
5 84 BB N
6 67 Wrist Y
7 81 BB N
65  14 57% 43%
8 52 BB Y
9 69 BB Y
10 68 BB Y
11 61 Wrist Y
12 62 BC Y
13 64 BB Y
14 56 BB Y
15 58 BB Y
16 46 BC Y
17 61 Wrist Y
18 68 BC Y
19 67 BC N
20 59 BC Y
61  7 15% 92%
Pc .41 .17 .33
AVF, Arteriovenous fistula; BB, brachiobasilic; BC, brachiocephalic; CAD
mellitus; ESRF DX, diagnosis leading to end-stage renal failure; F/U,
nonmaturation; Tob, tobacco use.
aContinuous variables are reported with  standard deviation.
bAccess, at the time of the index AVF construction, whether another access
cP values comparing the two variables.
dStatistically significant.enzyme-linked immunosorbent assay (ELISA analysis). “After surgical construction, the patients were seen in
he vascular surgery clinic at 2 and 6 weeks to assess for
urgical healing and AVF patency. Patients were monitored
ongitudinally until a mature AVF was achieved. If the AVF
as abandoned for another site and a new AVF con-
tructed, the follow-up ended for the abandoned access
ite. Intervention was recommended in AVFs with velocity
ndings consistent with stenosis. Patients with deep vein
egments underwent secondary superficialization through a
stula elevation procedure or a basilic vein transposition.
Determination of AVF maturation. Patients were
eemed to have a mature AVF when the first two of three
riteria were met for patients not yet receiving dialysis or at
east the third criterion was met if the patient required
ialysis:
. Vein diameter 0.6 mm.
. Flow volumes 600 mL/min.
. Complete two-needle cannulation for two-thirds or
more of all dialysis runs for 1 month after initiating
dialysis.
A duplex assessment of the AVFwas performed 6 weeks
fter AVF creation, but no specific timeframe from AVF
reation to the initial dialysis access was established, be-
ause early referral for AVF may lead to the diagnosis of
Tob CAD CVA Statin use
N N N N
N N N Y
Y N N Y
N N N Y
N N N Y
N N N Y
N N N N
14% 0% 0% 71%
N N N N
Y N N Y
N Y N Y
N Y N Y
N N N Y
N Y N Y
N N N N
N N N Y
N Y N Y
Y N Y Y
N N N Y
N N N Y
Y N N N
23% 31% 8% 77%
2 .7 .94 .47 .92
ary artery disease; CVA, cerebrovascular accident (stroke); DM, diabetes
-up; FSGS, focal sclerosis glomerulosclerosis; HTN, hypertension; NM,
as achieved or this was an initial access site.HTN
Y
Y
Y
Y
Y
Y
N
86%
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
100%
.8
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site wfailed AVF,” simply due to the nonuse of the dialysis
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August 2011456 Lee et alaccess. If the hemodialysis access could not be accessed or
duplex ultrasound imaging showed the vein segments were
too small for hemodialysis access, the patients could un-
dergo another hemodialysis access procedure. If the AVF
was thrombosed, the access procedure was considered a
failure. The patients were divided into a successful AVF
group and a failed AVF group for protein analysis.
Serum analysis MMP methods. Patient serum levels
of MMP-2, MMP-9, TIMP-2, and TIMP-4 were profiled
using commercially available ELISA kits (R&D Systems,
Minneapolis, Minn). Background activity in the negative
control wells was subtracted from the experimental wells in
reporting the data. The positive controls were the recom-
binant protein standards, and the negative controls were
the calibrator diluents. The sensitivity of the assay for each
protein was MMP-2, 0.0147 ng/mL; MMP-9, 0.156
ng/mL;TIMP-2, 0.011 ng/mL; andTIMP-4, 4.91 pg/mL.
Serum was obtained from peripheral blood collected
from the patient by centrifugation at 400g for 30 minutes
and was stored at –80°C until tested. Patient sera were
divided according to the clinical outcome of failed vs ma-
tured AVF. For testing, serum was thawed and diluted with
an appropriate concentration of dilution buffer. Samples
and controls were added to 96-well plates that were coated
with an antibody specific to the protein of interest. After 2
Table. Continued
ESRF DX Dialysis accessb Time on dialysis Time to AVF use
FSGS Catheter 5 NM
FSGS Catheter 2 Thromb
FSGS Catheter 13 NM
DM Initial 0 NM
HTN Initial 3 Thromb
DM Initial 0 NM
HTN Catheter 168 Thromb
57% 27 . . .
FSGS Catheter 9 10
HTN Catheter 1 5
DM Initial 0 10
DM Catheter 2 2
DM Initial 0 4
DM Catheter 48 3
DM Catheter 1 8
DM Initial 0 9
DM Catheter 1 3
DM Catheter 4 4
DM Catheter 5 4
HTN Initial 0 50
DM Catheter 13 4
69% 6.5 8.9
.80 .25hours of incubation, plates were washed and then a second- try antibody to the protein of interest, which was conju-
ated to horseradish peroxidase, was added. After 2 hours
f incubation, plates were washed and incubated with
ubstrate solution for 30minutes. An acid stop solution was
dded, and the plate was read on a SpectraMax 190 micro-
late reader (Molecular Devices, Sunnyvale, Calif) at 450
m, with wavelength correction at 540 nm. A ratio of
MP/TIMP was used as an indicator of MMP activity,
ith a higher ratio signifying higher activity.13
Statistical analysis. Results are reported as mean 
tandard deviation. Excel software (Microsoft Inc, Red-
ond,Wash) was used to perform a two-tailed t test, which
as used to compare groups with continuous variables, and
2 analysis for proportions. A difference with a value of
 .05 was considered significant.
ESULTS
Of the 20 patients who were enrolled, AVF maturation
as successful in 13 (age, 64.7 14.2 years) and failed in 7
age, 60.8  7 years; P  .41). The preoperative vein
iameters were similar in the matured group (0.37 0.014
m) and in the failed group (0.36  0.14 mm; P  .82).
here were 15% wrist fistulas in the mature group and 57%
rist fistulas in the failed group (P .17). The groups had
imilar comorbidities (Table). The average follow-up for
/U
Vein diameter, mmb
Flow volume
(mL/min) 2nd procBefore After
0.26 0.33 162 N
0.63 . . . . . . N
0.36 0.6 609 N
0.22 0.38 248 Y
0.38 . . . . . . N
0.23 0.37 300 N
0.41 . . . . . . N
.7 0.36  0.14 0.42  0.12 329.8  195 . . .
0.48 0.74 1435 Y
0.29 0.8 1048 Y
0.37 0.62 1300 Y
0.24 . . . . . . N
0.29 0.85 972 Y
0.23 0.84 1009 Y
0.41 0.80 1000 Y
0.56 1.3 4600 Y
0.67 1.0 1070 Y
0.22 . . . . . . N
0.42 0.79 1189 Y
0.3 0.99 1901 Y
0.34 0.84 800 Y
.5 0.37  0.14 0.87  0.18 1484  1075
.01d .82 .0005c .06F
3
1
5
10
3
2
2
3
17
18
16
2
15
3
8
22
3
26
18
50
30
17he matured AVF group was 18 months, and the average
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Volume 54, Number 2 Lee et al 457time to abandonment for the failed AVF group was 4
months. Catheter placement was required in 13 of 20
patients (65%) during the follow-up period.
At 1 month after the index AVF construction, no AVF
was deemed mature. The average time from AVF creation
to actual dialysis access was 8.9 months. A secondary fistula
elevation or transposition procedure was required in 11 of
13 patients who had matured AVF to allow for successful
access of the index AVF.
Of the seven patients that had a failed AVF, four
patients had a patent AVF but nonmaturation. One patient
in the nonmaturation group had a maximum AVF vein
diameter of 0.38 mm and a flow volume of 248 mL/min.
This patient underwent fistulogram and balloon angio-
plasty, with marginal success in the attempt to accelerate
maturation.
Significantly higher serum levels of MMP-2/TIMP-2
were found in patients who had AVFs that matured (23.8
0.8) compared with those that failed (20.6  0.9; P 
.003). Similarly, a trend toward increased serum levels of
MMP-9/TIMP-4 was found in patients with a successful
AVF (128.6  34.3) vs those with a failed AVF (40.2 
10.1; P  .06; Figs 1 and 2).
DISCUSSION
Since the National Kidney Foundation introduced the
DOQI, guidelines and access management criteria are be-
ing used to judge vascular access programs.2 In a recent
review of the natural history of autogenous fistulas for
first-time dialysis access, only 11% of primary AVFs ma-
tured without intervention, and 48% of the primary AVFs
were ultimately used for hemodialysis access. The mean
time to AVF maturation was 146 days, and the mean time
for AVF abandonment was 162 days.14
Given these results, many patients undergo repetitive
Fig 1. Significantly higher levels of matrix metalloproteinase-2
(MMP-2)/tissue inhibitor of metalloproteinase-2 (TIMP-2) ratios
are identified in the serum of patients whose arteriovenous fistula
successfully matured compared with the serum of patients whose
arteriovenous fistula failed (P  .003). Error bars show the stan-
dard deviation.unsuccessful procedures. To improve this clinical problem, mnvestigators have focused on vascular remodeling and vas-
ular pathology. An animal model has been used to evaluate
MPs, which would be an obvious choice because these
roteins have a well-established role in intimal hyperpla-
ia15 and vessel enlargement6,7 when it comes to AVF
aturation. The MMPs are a family of multidomain endo-
eptidases that regulate physiologic and pathologic vascu-
ar remodeling under conditions such as atherosclerosis,
rterial aneurysm, graft, and wound healing. The major
unction of MMPs is degrading extracellular matrix com-
onents, thereby allowing circulating cells and smooth
uscle cells to migrate into the vessel wall that under-
oes outward remodeling. MMPs also target nonmatrix
ubstrates such as cytokines (tumor necrosis factor-,
nterleukin-1) and growth factors (vascular endothelial
rowth factor, transforming growth factor-, basic fi-
roblast growth factor).16
Vascular cells (endothelium) and inflammatory cells
monocytes) can both produce MMPs. MMPs are often
ecreted as proenzymes (latent) and then are processed to
ctive forms. Enzymatic activation requires removal of a
rodomain secondary to conformational changes that re-
eal the catalytic site, and hence the basis for detection of
oth latent and activated MMPs by zymography.
The best recognized activity regulators are cell-
ssociated MT-MMPs and TIMPs. Using MMP-2 as an
xample, activation occurs via formation of a tertiary com-
lex containing MT1-MMP (activator), TIMP-2 (inhibi-
or), and MMP-2 on the endothelial cell surface. Equilib-
ium is maintained by balanced activities of these enzymes.
hus, theMMP/TIMP ratio is often used as an indicator of
MP activity, with a higher ratio indicating higher activ-
ty.13,17
The endothelium is an important source of MMPs in
he vascular wall.18 Endothelial injury can cause impaired
MP production and activity required for expansive re-
ig 2. Higher levels of matrix metalloproteinase-9 (MMP-9) to
issue inhibitor of metalloproteinase-4 (TIMP-4) ratios are identi-
ed in serum of patients who had successful maturation of their
rteriovenous fistula when compared to the serum of patients who
ad failure (P  .06). Error bars show the standard deviation.odeling.19 In particular, MMP-2 andMMP-9 activity has
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flow segment of an AVF to mature in animal mod-
els.6,7,15,20 However, intimal hyperplasia has also been
associated with increasedMMP-221 andMMP-9 activity.15
The relative contribution ofMMP activity to remodeling vs
intimal hyperplasia is not clearly known.4,22 Given the
critical role of expansive remodeling in preserving vessel
lumen and patency in fistula maturation, the MMP effect is
considered more beneficial than detrimental. Indeed, a
recent study demonstrates that MMPs are crucial in the
expansive remodeling of AVF in rats.7
This study is an attempt to evaluate biologic serum
markers to assess for the potential of AVF maturation in
trying to predict initial AVF maturation. Biomarkers
have demonstrated a great value in the diagnosis and
treatment of many cardiovascular disease entities, such as
troponin in the diagnosis of acute myocardial infarc-
tion23 and C-reactive protein in predicting cardiac risk.24
More recently, circulating biomarkers of fibrinogen, D-
dimer, and interleukin-6 have been suggested as areas of
interest in detecting the presence and progression of ab-
dominal aortic aneurysms25 and other types of vascular
injury.26 Circulating biomarkers offer diagnostic or prog-
nostic value by reflecting the disease state and predilection
based on plasma measurements of molecules or proteins.24
The clinical effect of using preoperative markers resides
with their use as a potential adjunct to other known clinical
parameters that best maximize AVF maturation, such as a
thorough physical examination, arterial inflow assessment,
and noninvasive vein mapping. The findings in this study,
with a limited number of patients, point to the potential use
of known enzymes and their inhibitors (MMP-2 and
TIMP-2) that are necessary in vascular remodeling. The
ELISA technique is readily available in many basic labora-
tories, and the potential application to clinical practice is
possible.
However, the data presented in this study demonstrate
relative value differences between patients with an AVF that
matured vs those with an AVF did not. Patient sample size
was small, and no significant differences were found in
traditional clinical parameters in predicting success. A
follow-up study designed to determine predictability is in
progress so that an ELISA can be performed in a prospec-
tive manner and an estimate of successful maturation can be
made.
Since the Fistula First Initiative, AVF prevalence has
increased from 24% to 57.5% in the United States from
2004 to December 2010.27 However, central vein catheter
use for implementation of dialysis has risen 1.5- to 3.0-fold
from 1996 to 2007 in the international community when
evaluating trends of rising AVF prevalence and decreasing
arteriovenous graft use.28
Others dispute the application of these numbers to the
United States. Spergel29 states that despite the rise in AVF
prevalence rate over the past several years since the Fistula
First Initiative in 2004, catheter use has remained flat, at
27% to 28%. This has left many difficulties in clinical care,
such as the quandary of an AV graft vs an AVF and catheter On the face of marginal or unusable veins.1 The use of
MPs in modulating practice patterns in deciding which
reatment option is best is potentially promising and worth
urther research.
A severe limitation of this study has been the wide
ariation in the definition of AVF maturation.4 Previous
urgical studies have defined adequate maturation as
eemed by the vascular surgeon and nephrologist accord-
ng to thrill characteristics and AVF diameter.30 Other
tudies have defined a mature AVF as multiple successful
annulation attempts for dialysis. Nephrologists have de-
ned maturation in other ways. Lok et al31 define AVF
aturation as the continuous use of the AVF for 1 month
ithin 6 months of AVF creation, regardless of secondary
nterventions required to mature the AVF. However, the
ialysis Access Consortium had the strictest definition of
VF maturation, where an AVF needs to have 8 of 12
uccessful dialysis sessions during a 30-day “suitability”
eriod within the first 150 days of AVF creation.3 The
OQI access group plans to publish guidelines for AVF
aturation in 2011.
SerumMMP levels are markers of inflammation and are
nown to be increased in renal failure. Patients with renal
ailure, but who are not yet receiving dialysis, have the
ighest levels of serum MMP-2. When patients begin dial-
sis, the MMP levels decrease but do not fall to control
evels.17 The data presented in this study used patients in
arious stages of kidney failure and were predialysis or were
eceiving hemodialysis. These data were confounded by
ncluding nondialysis patients in various stages of renal
nsufficiency together with those patients receiving hemo-
ialysis. MMP levels have been shown to decrease once a
atient is receiving hemodialysis, but not quite to levels
een in control patients without any renal insufficiency.
ronically, MMP levels could be serially tested to identify a
eak increase to when the timing of initial AVF should be
onstructed. Further data should be collected and stan-
ardized in patients who have not yet begun dialysis to
ssess the likelihood for AVF maturation.
ONCLUSIONS
MMP-2 and TIMP-2 levels were different among pa-
ients whose fistulas matured vs those whose fistulas did not
ature. Further follow-up studies to determine the pre-
ictability of AVF maturation using relative patient serum
evels of MMP-2 and TIMP-2 are ongoing.
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Dr Robert J. Hye (San Diego, Calif). The past decade has seen
increasing recognition of the value of autogenous arteriovenous (AV)
fistulas in the hemodialysis population. AV fistulas are associated with
better patency, reduced risk of infection and less mortality as com-
pared to AV grafts and catheters. The Centers of Medicare and
Medicaid Services (CMS) Fistula First project and Kidney Disease
Outcomes Quality Initiative (KDOQI) guidelines have aggressively
promoted the use of AV fistulas, and the prevalence in the U.S. has
increased from33% in January of 2004 to 56% in June of 2010. Inmy
own organization, SouthernCalifornia Kaiser Permanente, our fistula
prevalence now exceeds 70% with some centers over 85%.nd actually, an increasing rate of maturation failure of between
5% and 45%. Anatomic and demographic variables such as blood
essel diameter, distensibility, age, gender, diabetes, and race have
ll been associated with an increased early failure rate. Biologic
rocesses that either inhibit vasodilatation or result in neointimal
yperplasia have also been implicated as causing fistulas to fail to
ature as expected.
Dr Lee and his colleagues have chosen to examine the biologic
spects of fistula failure and specifically the role of the metallopro-
eases (MMP)-2,MMP-9 and their tissue inhibitors in this process.
similar presentation from their group last year focused on tissueevels of these molecules in regard to fistula maturation while this
eport concentrates on serum levels, a potentially more clinically
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August 2011460 Lee et aluseful tool. These proteases have been studied in a variety of
vascular diseases, and their role is complex, involving variation in
the expression of the proteases themselves as well as their regula-
tory inhibitors and other bioactive molecules.
Expression of metalloproteases has been studied in many
vascular diseases and has been found to be increased in both
patients with aneurysmal disease and chronic kidney disease. Pa-
tients with diabetic nephropathy have been reported to have both
increased and decreased levels. Interestingly, one of the effects of
statins is a reduction in expression and activity of MMP-9. The
exact role of these proteins in vascular remodeling is not entirely
defined as yet.
The ideal biophysiologic response to creation of an arterio-
venous fistula that matures has been described as increased shear
stress in both the inflow artery and outflow vein causing an increase
in superoxide production. This combines with nitric oxide to form
peroxynitrite which upregulates MMP production, enhancing va-
sodilatation by fragmenting the internal elastic lamina of the
vessels. Occlusion of the fistula or maturation failure occurs when
this process is interrupted or does not proceed as described. Thus,
the authors’ premise is that measuring MMP-2 and 9 activity and
their regulatory inhibitors before, or at the time of fistula creation,
may allow us to predict maturation. The results presented today,
although in a very small sample size, show that measurement of
metalloprotease activity expressed as a ratio of levels of the protease
to its inhibitor, is increased at the time of surgery in patients who
go on to develop usable arteriovenous fistulas.
While the results are appealing, a number of important issues
are not addressed in the manuscript or presentation and are the
basis of my questions. It is not clear to me when and from where
the blood samples were obtained. Was it from the dissected artery
or vein? Wouldn’t it have been be more valid to obtain the sample
preoperatively from a peripheral vein?
Most of the literature in this area documents increased MMP
activity in response to fistula creation and not increased levels at
baseline. Is their any evidence that patients with increased basal
levels also have increased expression or activity in response to fistula
creation?
Demographics of the patient population were not provided;
specifically, how many women and diabetics were in each group as
these are factors also associated with differing rates of maturation.
MMP expression varies with severity of renal failure, were the
successful and failed fistula group comparable in the severity of
their kidney disease?
Although a minimum criteria for vessel size is provided, there
is no further description of the range or if the sizes were compara-
ble between the successful and the failed group. Can you tell us
about that?Finally, the criteria for a successful fistula is fairly soft, three
successful dialysis runs. Were these patients all dialyzed in the same
i
vnit? Did you examine flow rates or clearance in these patients? Do
ou have any longer-term data on outcome in these patients?
It would be very useful to have a biomarker such as MMP-2 or
9 to add to our armamentarium to be able to predict AV fistula
aturation. I look forward to Dr Lee’s further endeavors in this
rea. I would like to thank the society for the opportunity to discuss
his interesting and well-presented paper.
Dr Eugene S. Lee. Thank you, Dr Hye, for discussing the
anuscript and your insights. I will answer the questions in order
resented. Blood samples were obtained from the dissected artery
ntraoperatively. In conducting the study, I was concerned that
btaining blood from the vein would unintentionally injure the
ein and/or the endothelium, and I wanted to avoid this possibil-
ty. I am not sure whether blood from the peripheral vein vs the
rtery is more valid. In the next set of samples, I plan to draw both
rterial and venous blood samples and will assay for theMMP levels
o see a difference.
In terms of MMP activity in response to fistula creation is
nteresting, as the literature has confirmed that patients with wors-
ning renal functioning have increased MMP activity until they go
n to dialysis. Tomy knowledge, there is no information regarding
erum MMP activity in response to fistula creation.
I plan to include demographic information in the final manu-
cript. However, the patient population is mainly a veteran or VA
opulation and this group in the study is entirely men with a vast
ajority of patients who are diabetic. In fact, a large percentage of
hese patients have diabetes as the cause of their renal failure.
As forMMP expression, I will have to further evaluate the data
ith regards to the severity of renal failure. Many of the patients
eferred for AV access were in chronic kidney disease (CKD) stage
, but at the time of surgery, there were a proportion of patients
ho had proceeded to CKD stage 5 (on hemodialysis) at the time
f arteriovenous fistula (AVF) creation, making the analysis a
ixed analysis of various levels of MMP expression. Clearly, this is
weakness in the purity of the data, but it does add further
redence to the fact that varying renal dysfunction may not signif-
cantly impact the differences seen in patients who mature their
stulae vs those who do not.
In terms of vessel sizes, I do not have exact vessel sizes in each
roup for you today, but I recollect that the vessel sizes were
omparable between groups. I hope to have this information in the
nal manuscript.
Finally, with respect to the rather “soft criteria” for successful
stula creation, I have been struggling with this definition.
DOQI has plans to publish a more uniform standard of a “suc-
essful” AVF in 2011. When one reviews the literature, the defini-
ion is quite varied; hopefully, soon we can come to a consensus. As
or these patients being dialyzed in the same unit, the answer to this
s no. In terms of flow rates, we do have information regarding flow
olumes and vein diameters, which I will have to review.
